期刊
INTENSIVE CARE MEDICINE EXPERIMENTAL
卷 10, 期 1, 页码 -出版社
SPRINGER
DOI: 10.1186/s40635-022-00435-w
关键词
ARDS; Diagnosis; Biomarker; Pathophysiology; Phenotype; Definition
资金
- innovative medicine initiative
- Dutch Lung Foundation
- Health Holland
- NIH [HL158906]
- Amsterdam UMC
The pathophysiology of acute respiratory distress syndrome (ARDS) leads to biological heterogeneity, making it difficult for pharmacological interventions to improve patient outcomes. This manuscript provides an overview of potential methods to capture the underlying biological heterogeneity of ARDS and discusses how this information could be used to redefine ARDS.
The pathophysiology of acute respiratory distress syndrome (ARDS) includes the accumulation of protein-rich pulmonary edema in the air spaces and interstitial areas of the lung, variable degrees of epithelial injury, variable degrees of endothelial barrier disruption, transmigration of leukocytes, alongside impaired fluid and ion clearance. These pathophysiological features are different between patients contributing to substantial biological heterogeneity. In this context, it is perhaps unsurprising that a wide range of pharmacological interventions targeting these pathophysiological processes have failed to improve patient outcomes. In this manuscript, our goal is to provide a narrative summary of the potential methods to capture the underlying biological heterogeneity of ARDS and discuss how this information could inform future ARDS redefinitions. We discuss what biological tests are available to identify patients with any of the following predominant biological patterns: (1) epithelial and/or endothelial injury, (2) protein rich pulmonary edema and (3) systemic or within lung inflammatory responses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据